Editor-in-Chief: Alaa Abd-Elsayed, MD, PhD
BACKGROUND: There is limited real-world evidence regarding the long-term effectiveness and safety outcomes related to spinal cord stimulation (SCS) for patients with chronic refractory pain.
CASE REPORT: This study included a total of 132 patients (73 had HF10); 53% was female. Mean Pretrial Numeric Pain Score for all patients was 8.4 ± 1.1 which decreased to 4.4 ± 2.0 at the end of one year (P < 0.0001). A 6% decrease in the percent of responders, between one month and one-year post-implant, was noted in the HF10 SCS compared to the 15% in standard SCS. A statistically significant decrease in pain relief in the male population (P = 0.02) and obese patients (P = 0.002) was observed. Most common complications: “IPG malfunction” (17%) for standard SCS and “IPG site pain” (12%) for HF10 SCS.
CONCLUSION: HF10 SCS is a viable alternative to standard SCS for chronic intractable pain conditions.
KEY WORDS: Complications, HF10, high-frequency stimulation, neuromodulation, patient outcomes, spinal cord stimulation